期刊文献+

267例浸润性乳腺癌分子亚型的临床病理特点分析 被引量:1

The Molecular Subtypes and Clinicopathologic Features in 267 Cases with Invasive Breast Cancer
暂未订购
导出
摘要 目的探讨浸润性乳腺癌分子亚型分布及其与临床病理特点的关系。方法选择2009年9月至2011年8月期间明确诊断的女性浸润性乳腺癌病例267例,分析雌激素受体(ER)、孕激素受体(PR)、HER-2的表达水平,以及乳腺癌分子亚型与临床病理特点的关系。结果 267例中52.0%为Luminal A型,16.5%为Luminal B型,Her-2(+)型占15.4%,Triple Negative型占16.1%。各分子亚型乳腺癌患者年龄集中在55岁以下,发病年龄有年轻化趋势。Luminal A型肿瘤分化程度较高,病理TNM分期偏早,晚期病例少,预后良好;Luminal B型组织学分级以Ⅱ级为主,患者中未绝经者比例高。Her-2(+)型乳腺癌肿瘤趋向于低分化,大长径;Triple Negative型乳腺癌患者诊断时原发肿瘤较大,组织学分级高,腋窝淋巴结转移者较多,具有更多不良预后因素。结论浸润性乳腺癌分子亚型分布差异存在统计学意义,并与其临床病理特点密切相关。 Objective To explore the relationship between the molecular subtypes and clinicopathologic features in patients with invasive breast cancer.Methods 267 female cases with invasive breast cancer between Sept 2009 and Aug 2011 were included in this study.The expression of estrogen receptor(ER),progestin receptor(PR) and HER-2 were detected and the relationship between molecular subtypes and clinicopathological features were analyzed.Results The proportions of four molecular subtypes in 267 cases were: luminal A subtype(52.0%),luminal B subtype(16.5%),HER-2+ type(15.4%),triple negative type(16.1%).The age of most patients were less than 55 years.The degree of tumor differentiation of luminal A subtype was higher,whose pathologic TNM stage was earlier,having less end-stage patients and better prognosis than those of others.Luminal B subtype was mostly characterized as histological grade Ⅱ and had high proportion of non-menopausal patients.The HER-2+ type trended to be poorly differentiated and had large diameter.In patients with triple negative type,the size of primary tumor at diagnosis was larger and histological grade was higher,while they had more axillary lymph nodes metastasized and more adverse prognosis factors than those of others.Conclusion The molecular subtype distribution of invasive breast cancer varied,which was closely related with clinicopathologic features.
出处 《宁夏医科大学学报》 2011年第11期1036-1039,共4页 Journal of Ningxia Medical University
关键词 乳腺癌 分子分型 临床病理 breast cancer molecular subtype clinicopathological features
  • 相关文献

参考文献12

  • 1Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [ J ]. JAMA,2006,295:2492 - 2502.
  • 2NCI. Director's challenge: toward a molecular classifica- tion of tumors, http: //grauts. nih. gov/grauts/guide/ rfa files/RFA2CA2982027, html.
  • 3Perou CM, Sorlie T, Eisen MB, et al. Molecular por-traits of human breast tumors [ J ]. Nature, 2000,406 : 747 - 752.
  • 4Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone and HER- 2 is associated with local anddistant recur- rence after breast - conserving therapy [ J ]. J Clin On- col ,2008,26 (14) :2373 - 2379.
  • 5Yu K, Lee CH, Tan PH, et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic population [J]. Clin Ca Res,2004,10(16) :5508 -5517.
  • 6袁中玉,王树森,朱美琴,郑磊,罗文标,周中梅,管忠震.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461. 被引量:55
  • 7陈小松,马传栋,陈灿铭,杨文涛,陆洪芬,周晓燕,柳光宇,狄根红,吴炅,陆劲松,韩企夏,邵志敏,沈镇宙,沈坤炜.乳腺癌分子分型与预后关系的研究[J].中华外科杂志,2008,46(18):1400-1403. 被引量:14
  • 8Delcasar JM, Martin A, Gareia C, et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters:Relationship with clinicopatholog- ical characteristics, biological features and prognosis [J]. Eur J Obstet Gynecol Reprod Biol,2008, 141: 147 - 152.
  • 9杨名添,戎铁华,黄植蕃,曾灿光,龙浩,傅剑华,林鹏,王欣,王思愚,王曦,唐军.可手术乳腺癌6263例临床分析[J].癌症,2005,24(3):327-331. 被引量:46
  • 10罗善山,陈俊强.乳腺癌分子分型的研究进展[J].微创医学,2009,4(3):257-259. 被引量:5

二级参考文献65

  • 1杨丽芳,宋三泰,李晓兵,江泽飞,刘晓晴,马维娜,乔西平,郭斯启.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,28(4):294-297. 被引量:11
  • 2余科达,狄根红,吴炅,陆劲松,沈坤炜,沈镇宙,邵志敏.ER(-)PR(+)乳腺癌辅助内分泌治疗的疗效[J].中国癌症杂志,2006,16(12):1011-1015. 被引量:13
  • 3van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415:530-536.
  • 4Sotiriou C, Neo SY, MeShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci U S A, 2003, 100: 10393- 10398.
  • 5Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 6Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer, 2001, 85:422-427.
  • 7Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat, 2004, 88 : 161-176.
  • 8Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 9Lohrisch C, Piccart M. An overview of HER2. Semin Oncol, 2001, 28(6 Suppl 18) :3-11.
  • 10Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol, 2002, 20:2736-2744.

共引文献110

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部